Identification of copy number alterations associated with the progression of DCIS to invasive ductal carcinoma

Ductal carcinoma in situ (DCIS) is a non-obligate precursor to invasive ductal carcinoma (IDC). Annotation of the genetic differences between the two lesions may assist in the identification of genes that promote the invasive phenotype. Synchronous DCIS and IDC cells were microdissected from FFPE tissue and analysed by molecular inversion probe (MIP) copy number arrays. Matched IDC and DCIS showed highly similar copy number profiles (average of 83% of the genome shared) indicating a common clonal origin although there is evidence that the DCIS continues to evolve in parallel with the co-existing IDC. Four chromosomal regions of loss (3q, 6q, 8p and 11q) and four regions of gain (5q, 16p, 19q and 20) were recurrently affected in IDC but not in DCIS. CCND1 and MYC showed increased amplitude of gain in IDC. One region of loss (17p11.2) was specific to DCIS. IDC-specific regions include genes with previous links to breast cancer progression and potential therapeutic targets such as AXL, SPHK1 and PLAUR.

[1]  R. Salunga,et al.  Gene expression profiles of human breast cancer progression , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[2]  C. Yamashiro,et al.  Extraction and Amplification of DNA From Formalin-Fixed, Paraffin-Embedded Tissues , 2002, Applied immunohistochemistry & molecular morphology : AIMM.

[3]  J. Minna,et al.  High-resolution chromosome 3p allelotyping of breast carcinomas and precursor lesions demonstrates frequent loss of heterozygosity and a discontinuous pattern of allele loss. , 2001, The American journal of pathology.

[4]  Tomas W. Fitzgerald,et al.  Breaking the waves: improved detection of copy number variation from microarray-based comparative genomic hybridization , 2007, Genome Biology.

[5]  J. Thiery,et al.  Integrated Genomic and Transcriptomic Analysis of Ductal Carcinoma In situ of the Breast , 2008, Clinical Cancer Research.

[6]  T. Sørlie,et al.  Molecular diversity in ductal carcinoma in situ (DCIS) and early invasive breast cancer , 2010, Molecular oncology.

[7]  M. Ranson,et al.  Peptides and small molecules targeting the plasminogen activation system: towards prophylactic anti-metastasis drugs for breast cancer. , 2008, Recent patents on anti-cancer drug discovery.

[8]  Derek Y. Chiang,et al.  The landscape of somatic copy-number alteration across human cancers , 2010, Nature.

[9]  S. Devries,et al.  Chromosomal alterations in ductal carcinomas in situ and their in situ recurrences. , 2000, Journal of the National Cancer Institute.

[10]  I. Bièche,et al.  Genetic pathways in the evolution of breast ductal carcinoma in situ , 2002, The Journal of pathology.

[11]  A. Ashworth,et al.  Tiling Path Genomic Profiling of Grade 3 Invasive Ductal Breast Cancers , 2009, Clinical Cancer Research.

[12]  T. Karn,et al.  Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer , 2008, Breast Cancer Research and Treatment.

[13]  Y. Niu,et al.  Genetic changes at specific stages of breast cancer progression detected by comparative genomic hybridization , 2009, Journal of Molecular Medicine.

[14]  Sean Davis,et al.  Molecular Grading of Ductal Carcinoma In situ of the Breast , 2008, Clinical Cancer Research.

[15]  P. O’Connell,et al.  Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci. , 1998, Journal of the National Cancer Institute.

[16]  S. Swain,et al.  Ductal carcinoma in situ, complexities and challenges. , 2004, Journal of the National Cancer Institute.

[17]  Hugo M. Horlings,et al.  Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets , 2009, Oncogene.

[18]  S. Tavaré,et al.  High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer , 2007, Genome Biology.

[19]  Jun Yao,et al.  Combined cDNA array comparative genomic hybridization and serial analysis of gene expression analysis of breast tumor progression. , 2006, Cancer research.

[20]  Kylie L. Gorringe,et al.  Copy Number Analysis Identifies Novel Interactions Between Genomic Loci in Ovarian Cancer , 2010, PloS one.

[21]  Mary E. Edgerton,et al.  Selective Genomic Copy Number Imbalances and Probability of Recurrence in Early-Stage Breast Cancer , 2011, PloS one.

[22]  James Ireland,et al.  Analysis of molecular inversion probe performance for allele copy number determination , 2007, Genome Biology.

[23]  J. Barrett,et al.  PIK3CA Mutations May Be Discordant between Primary and Corresponding Metastatic Disease in Breast Cancer , 2010, Clinical Cancer Research.

[24]  M. J. van de Vijver,et al.  Association of C‐MYC amplification with progression from the in situ to the invasive stage in C‐MYC‐amplified breast carcinomas , 2003, The Journal of pathology.

[25]  G. Sauter,et al.  Gene amplification in ductal carcinoma in situ of the breast , 2010, Breast Cancer Research and Treatment.

[26]  Karla Kerlikowske,et al.  Abrogated response to cellular stress identifies DCIS associated with subsequent tumor events and defines basal-like breast tumors. , 2007, Cancer cell.

[27]  H. Bu,et al.  Evidence of chromosomal alterations in pure usual ductal hyperplasia as a breast carcinoma precursor. , 2008, Oncology reports.

[28]  Li Li,et al.  High‐resolution genomic and expression analyses of copy number alterations in breast tumors , 2008, Genes, chromosomes & cancer.

[29]  H. Brentani,et al.  Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma , 2008, Breast Cancer Research.

[30]  J. Reis-Filho,et al.  Breast cancer precursors revisited: molecular features and progression pathways , 2010, Histopathology.

[31]  E. Petricoin,et al.  Malignant Precursor Cells Pre-Exist in Human Breast DCIS and Require Autophagy for Survival , 2010, PloS one.

[32]  M. Ringnér,et al.  Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics , 2010, Breast Cancer Research.

[33]  L. Rhodes,et al.  Pharmacological inhibition of sphingosine kinase isoforms alters estrogen receptor signaling in human breast cancer. , 2011, Journal of molecular endocrinology.

[34]  Y. Mo,et al.  Fatty acid synthase gene is up-regulated by hypoxia via activation of Akt and sterol regulatory element binding protein-1. , 2008, Cancer research.

[35]  Karla Kerlikowske,et al.  Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. , 2010, Journal of the National Cancer Institute.

[36]  P. Spellman,et al.  High quality copy number and genotype data from FFPE samples using Molecular Inversion Probe (MIP) microarrays , 2009, BMC Medical Genomics.

[37]  Ajay N. Jain,et al.  Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. , 2006, Cancer cell.

[38]  Jill P. Mesirov,et al.  Portraits of breast cancer progression , 2007, BMC Bioinformatics.

[39]  Randal L. Croshaw,et al.  Somatic mutations to CSMD1 in colorectal adenocarcinomas , 2008, Cancer biology & therapy.

[40]  L. Liotta,et al.  Identical allelic loss on chromosome 11q13 in microdissected in situ and invasive human breast cancer. , 1995, Cancer research.

[41]  Bjørn Tore Gjertsen,et al.  Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival , 2009, Proceedings of the National Academy of Sciences.

[42]  Mitsutaka Kadota,et al.  Identification of novel gene amplifications in breast cancer and coexistence of gene amplification with an activating mutation of PIK3CA. , 2009, Cancer research.

[43]  Mingming Jia,et al.  COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer , 2010, Nucleic Acids Res..

[44]  S. Lakhani,et al.  The diagnosis and management of pre-invasive breast disease: Genetic alterations in pre-invasive lesions , 2003, Breast Cancer Research.